临床经验
Copyright ©The Author(s) 2016.
世界华人消化杂志. 2016-07-08; 24(19): 3026-3031
在线出版 2016-07-08. doi: 10.11569/wcjd.v24.i19.3026
表1 患者一般情况及并发症情况
项目慢乙型肝炎肝硬化代偿期肝硬化失代偿期总体统计值P
年龄(岁)41.15±14.7849.71±10.1753.03±12.4847.07±14.54F = 32.0900.000
男性[n(%)]126/169(74.6)32/38(84.2)110/151(72.8)268/358(74.9)χ2 = 2.0090.035
ALT(μmol/L)169(10, 3887)37(10, 983)56(7, 1451)65(7, 3887)χ2 = 35.6820.000
血肌酐(μmol/L)65.21±15.4465.45±9.6574.66±43.0469.22±30.36F = 4.2660.015
HBV DNA (Log10 copies/mL)5.38(0.00, 9.30)5.15(0.00, 7.34)5.35(0.00, 8.58)5.35(0.00, 9.30)χ2 = 6.9980.030
e抗体阳性[n(%)]83/169(49.1)4/38(10.5)49/151(32.5)36/358(38.0)χ2 = 23.0090.000
并发症[n(%)]
高血压病14/169(8.3)2/38(5.3)12/151(7.9)28/358(7.8)χ2 = 0.3980.819
糖尿病9/169(5.3)4/38(10.5)13/151(8.6)26/358(7.3)χ2 = 1.9490.377
肾囊肿7/169(4.1)4/38(10.5)12/151(7.9)23/358(6.4)χ2 = 3.1100.211
肾结石5/169(3.0)1/38(2.6)3/151(2.0)9/358(2.5)χ2 = 0.3100.857
蛋白尿18/169(10.7)3/38(7.9)28/151(18.5)49/358(13.7)χ2 = 5.4120.067
表2 不同疾病进展患者e-GFR情况、肾功能异常情况
分组e-GFR[mL/(min•1.73 m2)]肾功能异常n1/n(%)
慢乙型肝炎组125.39±31.9116/169(9.5)
肝硬化代偿期118.59±22.863/38(7.9)
肝硬化失代偿期111.23±38.4438/151(25.2)
总体118.70±34.6257/358(15.9)
统计值F = 6.890χ2 = 16.726
P0.0100.000
表3 不同Child-Pugh分级肝硬化患者e-GFR情况、肾功能异常情况
Child-Pugh分级e-GFR[mL/(min•1.73 m2)]肾功能异常%(n1/n)
A级115.33±26.2515.38(8/52)
B级113.31±35.3617.19(11/64)
C级110.32±42.1430.14(22/73)
总体112.71±35.9221.69(41/189)
统计值F = 0.307χ2 = 5.047
P0.7360.080
表4 肾功能异常独立危险因素
因素单因素
多因素
OR值95%置信区间
POR值95%置信区间
P
下限上限下限上限
年龄1.0701.0451.0960.0001.0641.0920.000
性别2.3631.3034.2820.0052.2924.4180.013
诊断0.5440.3940.7520.0000.6660.4650.9550.027
HBeAg阳性0.7860.4331.4290.430
HBV DNA0.9390.8481.0380.221
蛋白尿0.9340.4572.3430.934
高血压2.7831.1896.5120.018
糖尿病1.2820.6433.5530.633
肾结石7.1391.85627.4680.00410.1982.48341.8810.001
肾囊肿2.4940.9766.3690.056

引文著录: 余晓阳, 赵守松. 慢性乙型肝炎病毒感染初治人群肾功能异常率及其高危因素回顾. 世界华人消化杂志 2016; 24(19): 3026-3031